• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

RSV prefusion F protein vaccine is safe and effective in preventing RSV infection

byDavid XiangandKiera Liblik
February 23, 2023
in Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A single dose of the respiratory syncytial virus (RSV) prefusion F protein vaccine had an acceptable safety profile in adults 60 years of age or older.

2. A single dose of the RSV prefusion F protein vaccine prevented RSV-related acute respiratory infections in adults 60 years of age or older as compared to a placebo. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: RSV is a significant cause of acute respiratory infections as well as lower respiratory tract disease in older adults or those with coexisting comorbidities. Treatment of RSV-associated illness is typically supportive, with no recommended vaccines or prophylaxis for older adults. Given the surge of RSV in the past year, it is critical that intervention and prevention strategies be investigated for vulnerable populations. However, a recent candidate RSV vaccine (RSVPreF3 OA) has been proposed to be effective in inducing an RSV-neutralizing antibody response in older adults. However, there is still a gap in knowledge as to understanding the efficacy of the RSVPreF3 OA vaccine in preventing RSV-related lower respiratory tract disease in adults 60 years of age or older. Overall, this study found that a single dose of the RSVPreF3 OA vaccine was efficacious in preventing RSV-related lower respiratory tract disease, RSV acute respiratory infection, and severe RSV lower respiratory tract disease in adults 60 years of age or older during one RSV season, regardless of RSV sub-type and baseline coexisting conditions and frailty status.

Click to read the study in NEJM

Relevant Reading: Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy

In-Depth [randomized controlled trial]: This randomized, placebo-controlled phase three trial was conducted in 17 countries. Patients who were 60 years of age or older and had not been enrolled in another RSV vaccine trial were eligible for the study. Conversely, patients who were not medically stable were ineligible for the study. Participants were followed for three consecutive RSV seasons in the Northern Hemisphere and at least two consecutive seasons in the Southern Hemisphere. The primary endpoint was RSV-related lower respiratory tract disease as confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). Outcomes in the primary analysis were assessed via a primary efficacy analysis with a conditional exact binomial method based on the Poisson model. Based on the primary analysis, with a median follow-up of 6.7 months, vaccine efficacy against RT-PCR–confirmed RSV-related lower respiratory tract disease was 82.6% (96.95% Confidence Interval [CI], 57.9 to 94.1), with seven cases (1.0 per 1000 participant-years) in the vaccine group and 40 cases (5.8 per 1000 participant-years) in the placebo group. Vaccine efficacy was 94.1% (95% CI, 62.4 to 99.9) against severe RSV-related lower respiratory tract disease (assessed on the basis of clinical signs or by the investigator) and 71.7% (95% CI, 56.2 to 82.3) against RSV-related acute respiratory infection. The RSVPreF3 OA vaccine was more reactogenic than the placebo, but most adverse events reported were mild to moderate in severity. In summary, this study demonstrated that a single dose of the RSVPreF3 OA vaccine had an acceptable safety profile and prevented RSV-related acute respiratory infection, lower respiratory tract disease, and severe RSV-related lower respiratory tract disease in adults 60 years of age or older.

RELATED REPORTS

Mycobacterium abscessus infections after cardiac surgery linked to hospital water system

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: infectious diseasepublic heathpulmonologyrespiratory syncytial virus (RSV)respirologyRSVRSV prefusion F protein vaccineRSV vaccinationvaccination
Previous Post

Dietary insoluble fiber intake may be associated with lower risk of hypertension

Next Post

BNT162b2 COVID-19 vaccine safe and efficacious in young children

RelatedReports

Standardized central line care practices reduce bloodstream infections
Infectious Disease

Mycobacterium abscessus infections after cardiac surgery linked to hospital water system

March 23, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]
Infectious Disease

Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus

March 20, 2023
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Chronic Disease

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

March 17, 2023
Next Post
AAP recommends disaster preparedness measures for children

BNT162b2 COVID-19 vaccine safe and efficacious in young children

Preterm birth associated with lower high school academic performance

Use of questionnaires and tools to assess suicide risk in adolescents in the Emergency Department

Sleep duration inversely related to childhood type 2 diabetes risk makers

Screen time and sedentary lifestyle associated with increased obesity rates among adolescents

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Febuxostat may be effective in preventing contrast-induced acute kidney injury
  • Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
  • United States patients receive subcutaneous fluids less frequently than intravenous fluids when compared to Canadian patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options